SMT201500213B - Alcune triazolopirazine, loro composizioni e metodi d'uso - Google Patents

Alcune triazolopirazine, loro composizioni e metodi d'uso

Info

Publication number
SMT201500213B
SMT201500213B SM201500213T SM201500213T SMT201500213B SM T201500213 B SMT201500213 B SM T201500213B SM 201500213 T SM201500213 T SM 201500213T SM 201500213 T SM201500213 T SM 201500213T SM T201500213 B SMT201500213 B SM T201500213B
Authority
SM
San Marino
Prior art keywords
triazolopirazine
compositions
methods
Prior art date
Application number
SM201500213T
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500213(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of SMT201500213B publication Critical patent/SMT201500213B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
SM201500213T 2009-12-31 2015-09-09 Alcune triazolopirazine, loro composizioni e metodi d'uso SMT201500213B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
PCT/CN2010/080499 WO2011079804A1 (en) 2009-12-31 2010-12-30 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

Publications (1)

Publication Number Publication Date
SMT201500213B true SMT201500213B (it) 2015-10-30

Family

ID=44226181

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500213T SMT201500213B (it) 2009-12-31 2015-09-09 Alcune triazolopirazine, loro composizioni e metodi d'uso

Country Status (38)

Country Link
US (8) US8987269B2 (it)
EP (5) EP3795573B1 (it)
JP (5) JP5337313B2 (it)
KR (3) KR101905350B1 (it)
CN (3) CN102906092B (it)
AU (2) AU2010338712B2 (it)
BR (1) BR112012016129B1 (it)
CA (1) CA2785749C (it)
CL (1) CL2012001752A1 (it)
CO (1) CO6612235A2 (it)
CU (1) CU24167B1 (it)
CY (2) CY1118250T1 (it)
DK (3) DK3511330T3 (it)
DO (1) DOP2012000188A (it)
EA (2) EA025466B1 (it)
EC (1) ECSP12012011A (it)
ES (4) ES2726152T3 (it)
GT (1) GT201200220A (it)
HK (2) HK1194071A1 (it)
HR (3) HRP20221090T1 (it)
HU (3) HUE059696T2 (it)
IL (2) IL220433B (it)
LT (1) LT3795573T (it)
ME (1) ME02211B (it)
MX (1) MX336996B (it)
MY (1) MY179933A (it)
NI (1) NI201200118A (it)
NZ (1) NZ601128A (it)
PE (3) PE20160588A1 (it)
PL (3) PL3511330T3 (it)
PT (3) PT2719699E (it)
RS (3) RS63612B1 (it)
SG (1) SG181781A1 (it)
SI (2) SI2719699T1 (it)
SM (1) SMT201500213B (it)
UA (1) UA107822C2 (it)
WO (1) WO2011079804A1 (it)
ZA (1) ZA201205730B (it)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601128A (en) * 2009-12-31 2014-12-24 Hutchison Medipharma Ltd Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
CN107674073B (zh) * 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
EP2831073B1 (en) * 2012-03-30 2020-12-09 Rhizen Pharmaceuticals S.A. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
RU2655604C2 (ru) 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
JP5894714B1 (ja) 2013-03-06 2016-03-30 アストラゼネカ アクチボラグ 上皮成長因子受容体の活性化変異型のキナゾリン阻害剤
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
AU2013402175B2 (en) * 2013-09-30 2017-09-07 Handok Inc. Novel triazolopyrazine derivative and use thereof
PL3087070T3 (pl) * 2013-12-26 2018-03-30 Ignyta, Inc. Pochodne pirazolo[1,5-a]pirydyny i sposoby ich zastosowania
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CN106928233B (zh) * 2015-12-31 2021-02-12 上海医药集团股份有限公司 喹啉类化合物的盐，其晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
US11814363B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Morphic forms of danicopan
AU2019340569B2 (en) * 2018-09-11 2022-06-09 Astrazeneca Ab Improved method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20210111779A (ko) 2018-12-14 2021-09-13 베타 파마, 인크. C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
CN115362162A (zh) * 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
CA3193755A1 (en) * 2020-09-28 2022-03-31 Codexis, Inc. Engineered biocatalysts and methods for synthesizing chiral amines
CN117222634A (zh) * 2020-12-16 2023-12-12 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
KR102659095B1 (ko) 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
TW202421146A (zh) 2022-07-08 2024-06-01 瑞典商阿斯特捷利康公司 用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合
WO2024026410A2 (en) * 2022-07-29 2024-02-01 Baylor College Of Medicine Neurotrophic receptor tyrosine kinase (ntrk) inhibitors and methods using same
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法
WO2024148089A1 (en) * 2023-01-04 2024-07-11 Blueprint Medicines Corporation Cdk2 inhibitors
GB202300923D0 (en) * 2023-01-20 2023-03-08 Macfarlan Smith Ltd Novel polymorphic forms of savolitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
JP2007516180A (ja) * 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
CA2573362A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP2008509987A (ja) 2004-08-18 2008-04-03 ファルマシア アンド アップジョン カンパニー リミテッド ライアビリティ カンパニー トリアゾロピリジン化合物
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
BRPI0608160A2 (pt) 2005-02-16 2010-11-09 Astrazeneca Ab anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
AP3433A (en) * 2005-12-21 2015-10-31 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modultors
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
CA2651979A1 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
NZ575548A (en) 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
PT2081937E (pt) * 2006-10-23 2012-10-15 Sgx Pharmaceuticals Inc Moduladores de proteína-cinase de triazolo-piridazina
US8507489B2 (en) 2006-10-23 2013-08-13 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ME01507B (me) 2006-11-22 2014-04-20 Incyte Holdings Corp Imidazotriazini i imidazopirimidini kao inhibitori kinaze
EA200901157A1 (ru) 2007-04-10 2010-04-30 ЭсДжиИкс ФАРМАСЬЮТИКАЛЗ, ИНК. Конденсированные кольцевые гетероциклические модуляторы киназы
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
KR20100128305A (ko) 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
MX2010012528A (es) 2008-05-22 2010-12-02 Amgen Inc Heterociclos como inhibidores de proteina cinasa.
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
AU2010283806A1 (en) * 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EP2467383A1 (en) * 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
NZ601128A (en) * 2009-12-31 2014-12-24 Hutchison Medipharma Ltd Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
CN107674073B (zh) 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物

Also Published As

Publication number Publication date
PL3511330T3 (pl) 2021-04-19
KR101434766B1 (ko) 2014-08-26
IL239997A (en) 2017-11-30
US10512645B2 (en) 2019-12-24
US20120245178A1 (en) 2012-09-27
EP3511330B1 (en) 2020-09-30
ME02211B (me) 2016-02-20
JP6486999B2 (ja) 2019-03-20
PL2719699T3 (pl) 2016-01-29
HUE052828T2 (hu) 2021-05-28
RS63612B1 (sr) 2022-10-31
US20120264739A1 (en) 2012-10-18
MX336996B (es) 2016-02-09
PE20130375A1 (es) 2013-04-10
PT2719699E (pt) 2015-09-30
US9956218B2 (en) 2018-05-01
PT3795573T (pt) 2022-09-15
SI3511330T1 (sl) 2021-01-29
JP6194046B2 (ja) 2017-09-06
US20210154192A1 (en) 2021-05-27
HUE025504T2 (en) 2016-02-29
HRP20221090T1 (hr) 2022-11-25
JP2018009004A (ja) 2018-01-18
JP2016155848A (ja) 2016-09-01
KR20120125261A (ko) 2012-11-14
KR101905350B1 (ko) 2018-11-30
US8507487B2 (en) 2013-08-13
CN106117248B (zh) 2019-01-22
BR112012016129A2 (pt) 2016-05-31
ECSP12012011A (es) 2012-10-30
JP5337313B2 (ja) 2013-11-06
SI2719699T1 (sl) 2015-12-31
ZA201205730B (en) 2016-01-27
US20170027934A1 (en) 2017-02-02
EP2719699B1 (en) 2015-07-08
EP2966075A1 (en) 2016-01-13
US20180263977A1 (en) 2018-09-20
EP2966075B1 (en) 2019-02-27
EP3795573B1 (en) 2022-07-06
GT201200220A (es) 2014-12-22
WO2011079804A1 (en) 2011-07-07
PT3511330T (pt) 2020-12-24
IL220433B (en) 2018-01-31
DK2719699T3 (en) 2015-08-24
ES2726152T3 (es) 2019-10-02
RS54217B1 (en) 2015-12-31
EP3795573A1 (en) 2021-03-24
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
US20150368271A1 (en) 2015-12-24
AU2015203480B2 (en) 2017-10-26
EA025466B1 (ru) 2016-12-30
EA201691461A1 (ru) 2017-01-30
CU24167B1 (es) 2016-03-31
EP2519524A1 (en) 2012-11-07
CO6612235A2 (es) 2013-02-01
JP2013209418A (ja) 2013-10-10
AU2015203480A1 (en) 2015-07-16
CA2785749C (en) 2017-11-28
US11896592B2 (en) 2024-02-13
JP2013516393A (ja) 2013-05-13
US20200179377A1 (en) 2020-06-11
LT3795573T (lt) 2022-11-10
JP6647434B2 (ja) 2020-02-14
DK3795573T3 (da) 2022-09-19
AU2010338712B2 (en) 2015-04-02
EP2719699A1 (en) 2014-04-16
US8987269B2 (en) 2015-03-24
ES2546635T3 (es) 2015-09-25
EA030141B1 (ru) 2018-06-29
CN106432225B (zh) 2019-02-19
CY1118250T1 (el) 2017-06-28
KR20170098324A (ko) 2017-08-29
CN106117248A (zh) 2016-11-16
KR20140059307A (ko) 2014-05-15
IL239997A0 (en) 2015-08-31
CN102906092B (zh) 2016-08-03
UA107822C2 (en) 2015-02-25
HRP20202017T1 (hr) 2021-02-19
CY1123777T1 (el) 2022-03-24
CU20120101A7 (es) 2012-10-15
US20240139182A1 (en) 2024-05-02
AU2010338712A1 (en) 2012-07-12
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
HK1194071A1 (en) 2014-10-10
CN102906092A (zh) 2013-01-30
RS61281B1 (sr) 2021-02-26
JP2019108345A (ja) 2019-07-04
PE20160588A1 (es) 2016-07-09
ES2927146T3 (es) 2022-11-02
PL3795573T3 (pl) 2022-11-21
CA2785749A1 (en) 2011-07-07
CN106432225A (zh) 2017-02-22
NZ601128A (en) 2014-12-24
BR112012016129B1 (pt) 2020-11-03
CL2012001752A1 (es) 2013-01-25
EP2519524A4 (en) 2013-07-03
KR101771299B1 (ko) 2017-08-24
SG181781A1 (en) 2012-07-30
MX2012007756A (es) 2012-11-06
MY179933A (en) 2020-11-19
EP3511330A1 (en) 2019-07-17
US10946014B2 (en) 2021-03-16
EA201200951A1 (ru) 2013-09-30
HK1216880A1 (zh) 2016-12-09
HRP20150952T1 (hr) 2015-10-09
DK3511330T3 (da) 2020-12-21
HUE059696T2 (hu) 2022-12-28

Similar Documents

Publication Publication Date Title
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
SMT201600226B (it) Alcune amminopirimidine, loro composizioni e metodi per il loro uso
SMT201600388B (it) Ligandi leganti opsina, composizioni e metodi d'uso
SMT201400055B (it) Composti di tioacetato, composizioni e metodi d'uso
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI1014854A2 (pt) "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
SMT201400181B (it) Composizioni per vasocostrizione e metodi d'uso
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI1005292A2 (pt) composição de decapagem e uso da composição
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112012000735A2 (pt) "métodos, kits e conjuntos de compostos"
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
BRPI1007494A2 (pt) composto e uso do mesmo
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI1005670A8 (pt) composições adjuvantes e processos de uso.
BRPI1008215A2 (pt) "composição azeotrópica"
BRPI0917707A2 (pt) composições biocidas potencializadas e métodos de uso